Zero Candida Announces First Intellectual Property in South Africa

Company is in the process to be listed on the TSX Venture Exchange (Canada) at a Proposed Valuation of 40 million Canadian Dollars

TEL AVIV, IsraelJune 18, 2024 /CNW/ — Zero Candida (the “Company” or “ZC “) an Israeli FemTech medical device start-up is pleased to announce its first INTELLECTUAL PROPERTY – 2022/09265 Granted + PCT patent PCT-IL 2023050243 in South Africa.

Are you an angel?

Public Announcements

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Supports GLP preclinical testing and planned Q4 2026 clinical study of at least 100 women VANCOUVER, BC, Feb. 17, 2026 /PRNewswire/ — Zero Candida Technologies,…

Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device

Zero Candida Technologies, Inc. (TSXV: ZCT)(OTCQB: ZCTFF)(FSE: 9L2) (the “Company” or “ZCT”), a FemTech medical device company focused on revolutionizing women’s health, is pleased to…

Zero Candida Technologies Reports Financial Results for Three and Six Months Ended June 30, 2025 and Provides Business Update

Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the “Company” or “ZCT”), a Femtech company developing a SMART, AI-driven medical device to…